Teachers Retirement System of The State of Kentucky Has $7.80 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Teachers Retirement System of The State of Kentucky boosted its holdings in United Therapeutics Co. (NASDAQ:UTHRGet Rating) by 85.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 43,450 shares of the biotechnology company’s stock after purchasing an additional 20,062 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in United Therapeutics were worth $7,795,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in UTHR. MCF Advisors LLC bought a new stake in shares of United Therapeutics in the 1st quarter valued at $34,000. NuWave Investment Management LLC bought a new stake in United Therapeutics in the first quarter valued at $53,000. Rockefeller Capital Management L.P. raised its holdings in shares of United Therapeutics by 243.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 254 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 180 shares during the period. Laurel Wealth Planning LLC bought a new position in shares of United Therapeutics during the 1st quarter worth about $54,000. Finally, Sandy Cove Advisors LLC bought a new stake in United Therapeutics in the 1st quarter valued at about $58,000. 95.57% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 3,500 shares of the business’s stock in a transaction dated Tuesday, August 23rd. The stock was sold at an average price of $224.96, for a total value of $787,360.00. Following the sale, the director now directly owns 2,835 shares in the company, valued at approximately $637,761.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Raymond Dwek sold 2,160 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $241.29, for a total value of $521,186.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher Causey sold 3,500 shares of the business’s stock in a transaction on Tuesday, August 23rd. The shares were sold at an average price of $224.96, for a total value of $787,360.00. Following the sale, the director now owns 2,835 shares in the company, valued at $637,761.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,212 shares of company stock worth $6,330,244. 12.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on UTHR. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $225.00 to $238.00 in a research report on Tuesday, May 24th. Wedbush increased their target price on shares of United Therapeutics from $236.00 to $263.00 and gave the company an “outperform” rating in a report on Tuesday, May 24th. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, September 9th. Credit Suisse Group increased their price objective on shares of United Therapeutics from $219.00 to $247.00 and gave the company an “outperform” rating in a research note on Tuesday, May 24th. Finally, HC Wainwright boosted their target price on United Therapeutics from $248.00 to $255.00 and gave the stock a “buy” rating in a research note on Tuesday, May 24th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $250.14.

United Therapeutics Stock Down 1.1 %

UTHR opened at $218.11 on Friday. United Therapeutics Co. has a twelve month low of $158.38 and a twelve month high of $245.48. The company’s 50-day moving average price is $224.94 and its two-hundred day moving average price is $208.59. The stock has a market cap of $9.93 billion, a price-to-earnings ratio of 16.51, a PEG ratio of 4.24 and a beta of 0.54. The company has a quick ratio of 7.83, a current ratio of 8.10 and a debt-to-equity ratio of 0.19.

United Therapeutics (NASDAQ:UTHRGet Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported $2.41 earnings per share for the quarter, missing the consensus estimate of $4.10 by ($1.69). United Therapeutics had a net margin of 35.27% and a return on equity of 15.50%. The firm had revenue of $466.90 million for the quarter, compared to the consensus estimate of $461.06 million. During the same period last year, the company posted $3.65 earnings per share. United Therapeutics’s revenue for the quarter was up 4.6% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics Co. will post 15.21 earnings per share for the current year.

United Therapeutics Profile

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Stories

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRGet Rating).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.